- The overall study dropout rate of ~4.4% is far below rates typically observed with other FDA approved chronic pain medicines - Based on the current Phase 2b trial enrollment pace and the interim ...

- New Synthetic Process to be Used for Phase 3 Development Provides Higher Manufacturing Yields and Reduces Costs Versus Naturally Harvested Halneuron® - ATLANTA, GA / ACCESS Newswire / December 2, ...

ATLANTA, GEORGIA / ACCESS Newswire / November 11, 2025 / Dogwood Therapeutics, Inc. (Nasdaq:DWTX) (the "Company"), a development-stage biotechnology company developing new medicines to treat pain and ...

All-Stock Licensing Deal for Treatment of Cancer Related Pain On September 29, 2025, Dogwood Therapeutics, Inc. (NASDAQ:DWTX) announced a royalty-free, global license deal with Serpin Pharma for SP16 ...

On September 29, 2025, Dogwood Therapeutics, Inc. (NASDAQ:DWTX) announced a royalty-free, global license deal with Serpin Pharma for SP16 for the management of cancer related pain (CRP), including a ...

Dogwood Therapeutics, Inc., a clinical-stage biotechnology company, has secured a royalty free, global license to develop Serpin Pharma’s intravenous (IV) formulation of SP16 to manage cancer related ...

-A first-in-class LRP1 agonist, SP16 phase 1b Chemotherapy Induced Neuropathy (CIPN) Study fully funded by the National Cancer Institute, with projected patient enrollment beginning in the first half ...

ATLANTA - Dogwood Therapeutics, Inc. (NASDAQ:DWTX), a clinical-stage biotech company with a market capitalization of $10.55 million, has secured a royalty-free global license for Serpin Pharma’s SP16, ...

ATLANTA, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (DWTX) (“Dogwood” or the “Company”), a clinical-stage biotechnology company developing new medicines to treat pain and neuropathy ...

(RTTNews) - Dogwood Therapeutics, Inc. (DWTX) said, in an all-stock transaction, it has secured a royalty free, global license to develop Serpin Pharma's intravenous formulation of SP16 to manage ...